Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgrastim schedules for febrile neutropenia prophylaxis in breast cancer
NCT02816164Phase 4Completed
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Sep 2016
- Primary completion
- Feb 2019
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 4 trial of filgrastim in febrile neutropenia (FN), sponsored by Ottawa Hospital Research Institute. Started Sep 2016; status: completed.
02
Drugs
filgrastim
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on NCT02816164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02816164.